IceCure Medical (ICCM) announced it has received an Intention to Grant Notice from the European Patent Office, EPO, for its invention titled “Cryogenic System Connector”. This invention was recently granted a patent in the United States. “We are experiencing increased momentum in the growth of our intellectual property assets, further demonstrating our global leadership in cryoablation. Europe is a major market for us, with several key distributors selling ProSense and numerous new and ongoing independent clinical studies initiated by doctors who are using our cryoablation technology across many indications,” stated IceCure’s CEO, Eyal Shamir.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- Icecure Medical Appoints New Board Director with Financial Expertise
- IceCure Medical’s Cryoablation Success in Kidney Tumors
- IceCure Medical’s ProSense cryoablation shows efficacy in kidney tumor study
- IceCure Medical Sees Strong Growth Amid ProSense® Adoption
- IceCure Medical price target raised to $4.60 from $4.16 at Brookline
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
